» Articles » PMID: 31921395

Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery

Overview
Specialty Biotechnology
Date 2020 Jan 11
PMID 31921395
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Advancements in biotechnology and protein engineering expand the availability of various therapeutic proteins including vaccines, antibodies, hormones, and growth factors. In addition, protein drugs hold many therapeutic advantages over small synthetic drugs in terms of high specificity and activity. This has led to further R&D investment in protein-based drug products and an increased number of drug approvals for therapeutic proteins. However, there are many biological and biopharmaceutical obstacles inherent to protein drugs including physicochemical and enzymatic destabilization, which limit their development and clinical application. Therefore, effective formulations of therapeutic proteins are needed to overcome the various physicochemical and biological barriers. In current medical practice, protein drugs are predominantly available in injectable formulations, which have disadvantages including pain, the possibility of infection, high cost, and low patient compliance. Consequently, non-invasive drug delivery systems for therapeutic proteins have gained great attention in the research and development of biomedicines. Therefore, this review covers the various formulation approaches to optimizing the delivery properties of protein drugs with an emphasis on improving bioavailability and patient compliance. It provides a comprehensive update on recent advancements in nanotechnologies with regard to non-invasive protein drug delivery systems, which is also categorized by the route of administrations including oral, nasal, transdermal, pulmonary, ocular, and rectal delivery systems.

Citing Articles

Ionic liquids as stabilisers of therapeutic protein formulations: a review of insulin and monoclonal antibodies.

Tien S, Kayser V Biophys Rev. 2025; 17(1):89-101.

PMID: 40060006 PMC: 11885717. DOI: 10.1007/s12551-024-01261-y.


Dissolving microneedle patch for transdermal delivery of perindopril erbumine.

Altaf Z, Ahmad Z, Mahmood A, Shchinar S, Latif R Inflammopharmacology. 2025; .

PMID: 40009346 DOI: 10.1007/s10787-025-01696-z.


Engendered nanoparticles for treatment of brain tumors.

Soleymani S, Doroudian M, Soezi M, Beladi A, Asgari K, Mobarakshahi A Oncol Res. 2024; 33(1):15-26.

PMID: 39735671 PMC: 11671406. DOI: 10.32604/or.2024.053069.


Intravitreal long-term sustained ranibizumab delivery using injectable microgel-embedded hydrogel.

Lee S, Park J, Hong H, Son J, Kim B, Chung J Asian J Pharm Sci. 2024; 19(5):100947.

PMID: 39474125 PMC: 11513470. DOI: 10.1016/j.ajps.2024.100947.


Enhanced Oral Efficacy of Semaglutide via an Ionic Nanocomplex with Organometallic Phyllosilicate in Type 2 Diabetic Rats.

Kim G, Song J, Han H Pharmaceutics. 2024; 16(7).

PMID: 39065583 PMC: 11280289. DOI: 10.3390/pharmaceutics16070886.


References
1.
Yoshida M, Kamei N, Muto K, Kunisawa J, Takayama K, Peppas N . Complexation hydrogels as potential carriers in oral vaccine delivery systems. Eur J Pharm Biopharm. 2016; 112:138-142. DOI: 10.1016/j.ejpb.2016.11.029. View

2.
Liao A, Ma W, Wang C, Yeh M . Penetration depth, concentration and efficiency of transdermal α-arbutin delivery after ultrasound treatment with albumin-shelled microbubbles in mice. Drug Deliv. 2014; 23(7):2173-2182. DOI: 10.3109/10717544.2014.951102. View

3.
Yavuz B, Bozdag Pehlivan S, Unlu N . Dendrimeric systems and their applications in ocular drug delivery. ScientificWorldJournal. 2014; 2013:732340. PMC: 3874982. DOI: 10.1155/2013/732340. View

4.
Makhlof A, Fujimoto S, Tozuka Y, Takeuchi H . In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur J Pharm Biopharm. 2010; 77(2):216-24. DOI: 10.1016/j.ejpb.2010.12.008. View

5.
Yang H, Tyagi P, Kadam R, Holden C, Kompella U . Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 2012; 6(9):7595-606. DOI: 10.1021/nn301873v. View